API
< Back to all clusters
[BUSINESS] · United States, South Korea · 5 sources

started · updated

SK Biopharm seeks FDA approval to expand epilepsy drug use

SK Biopharm has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the treatment indications for its epilepsy drug, cenobamate, marketed as Xcopri in the United States.

The application seeks to include patients aged 12 and older with primary generalized tonic-clonic seizures (PGTC). This move follows positive results from a global Phase 3 clinical trial involving 169 patients across 12 countries. The study reported a 71.9% median reduction in PGTC seizure frequency for the cenobamate group, compared to a 39.6% reduction in the placebo group.

In addition to the PGTC indication, SK Biopharm is pursuing a lifecycle management strategy that includes expanding the drug's use to pediatric patients with focal onset seizures and seeking approval for an oral suspension formulation to improve administration convenience for those who have difficulty swallowing tablets.

Entities

Lee Dong-hoon · SK Biopharm · U.S. Food and Drug Administration · Xcopri